

Medication Treatment of COVID-19

Standard Orders

MILDLY ILL OUTPATIENTS OR INPATIENTS

WHO ARE: asymptomatic or minimally symptomatic and hospitalized for reasons other than COVID-19

Addressograph/Place Label Here

These orders are to be used as a guideline and do not replace sound clinical judgement and professional practice standards.

Patient allergy and contraindications must be considered when completing these orders.

- Automatically activated (If not in agreement with an order cross out and initial).
 Requires a check(✓) for activation

Drug Allergies: Unknown No Yes (describe)

Weight: kg Estimated Actual

MEDICATION ORDERS

CRITERIA & GENERAL ORDERS

MILDLY ILL (Groups 1 to 4) Do not require supplemental oxygen (above their baseline), intravenous fluids, or physiologic support.

Mandatory Criteria:

- Age 18 or over

For:

- Group 1
 Group 2
 Group 3
 Group 4

- paxlovid** (nirmatrelvir 300 mg, ritonavir 100 mg) po BID x 5 days (if duration of symptoms less than or equal to 5 days – CAVEATS: a) check drug-drug interactions; b) Not recommended in pregnancy; c) not recommended in severe liver disease (Child-Pugh class C) d) if eGFR 30-59 ml/min use half dose of nirmatrelvir
 paxlovid (nirmatrelvir 150 mg, ritonavir 100 mg) po BID x 5 days;
do not use, if eGFR less than 30 mL/min

OR

- remdesivir** 200 mg IV on day 1 then 100 mg IV daily x 2 days, if duration of COVID-19 symptoms less than or equal to 7 days (for pregnancy would only use if risk of hospital admission is high AND patient is fully informed of limited data on use)

If antiviral medications and MAB unavailable or contraindicated and if symptoms duration less or equal to 7 days may consider:

- Fluvoxamine** 50 mg po daily x 1 then 50 mg BID x 1 day then 100 mg po BID for a total treatment course of 15 days (Grade B evidence)

OR

- Inhaled Budesonide MDI** 800 mcg BID x 14 days

Group 1: Immunocompromised (see page 2 for criteria) individuals regardless of vaccination status or prior infection with SARS-CoV-2
Group 2: (all 3 criteria must be met)

- Unvaccinated (zero doses) or partially vaccinated (1 of 2 doses) AND
 No prior history of COVID-19 in the last 6 months AND
 Age greater than 40 years old

Group 3: (all 3 criteria plus 1 risk factor)

- Unvaccinated (zero doses) or partially vaccinated (1 or 2 doses) AND
 No prior history of COVID-19 AND
 Age 18-40 years old AND
 One condition/risk factor such as diabetes, smoking, obesity, heart disease, kidney disease, lung disease, liver disease, cancer, mental health disorders, pregnancy, tuberculosis treatment

Group 4:

- No history of a test confirmed COVID-19 infection in the last 6 months AND
 Individual self-identifies as Indigenous (First Nations, Metis or Inuit) and is 40 years or older OR
 Individual is 50 years or older AND
 Completely vaccinated (2 doses of 2-dose series or 1-dose of a single-dose series) of COVID-19 vaccine AND
 Greater than 4 months have elapsed since last vaccine (less than 14 days post booster dose are also candidates)
 One condition/risk factor such as diabetes, smoking, obesity, heart disease, kidney disease, lung disease liver disease, cancer, mental health disorders, pregnancy, tuberculosis treatment

- Droplet and Contact Precautions - appropriate zone (orange, red PPE requirements)

- Airborne Precautions (N95 mask and associated PPE to be donned) if performing aerosol generating medical procedures

- Establish peripheral venous access

- Observe and monitor for signs and symptoms of anaphylaxis or other hypersensitivity reaction throughout infusion and for at least 1 hour following completion of infusion for Sotrovimab

Laboratory Investigations (if not done at triage):

- hCG (if child bearing age)

- creatinine

- Viral studies: swab for COVID-19 testing

- GeneXpert PCR test

- Abbott ID rapid antigen test

- Other _____

PRESCRIBER'S SIGNATURE: _____ PRINTED NAME: _____ Date _____ Time _____

Order Transcribed _____ FAX TO PHARMACY _____

Date: _____ Time: _____ Init: _____ Date: _____ Time: _____ Init: _____

Group 1: Immunocompromised individuals that have **one or more of the following** conditions:

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., greater or equal to 20 mg/day prednisone or equivalent when administered for greater or equal to 2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, Tumor-necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory